These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 2545783)

  • 1. The release of C5a in complement-activated serum does not require C6.
    Biesecker G; Wagner JL; Hugli TE
    J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
    Hammer CH; Hänsch G; Gresham HD; Shin ML
    J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Terminal complement components play a role in the expression of C5a.
    Gresham HD; Renfer L; Hammer CH; Frank MM
    J Immunol; 1987 Feb; 138(3):838-41. PubMed ID: 3805718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement-mediated serum cytotoxicity for Leishmania major amastigotes: killing by serum deficient in early components of the membrane attack complex.
    Hoover DL; Berger M; Hammer CH; Meltzer MS
    J Immunol; 1985 Jul; 135(1):570-4. PubMed ID: 3998474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative inefficiency of terminal complement activation.
    Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
    J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
    Kroshus TJ; Rollins SA; Dalmasso AP; Elliott EA; Matis LA; Squinto SP; Bolman RM
    Transplantation; 1995 Dec; 60(11):1194-202. PubMed ID: 8525509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human peritoneal macrophages. Production in vitro of the active terminal complement components C5 to C9 and a functional alternative pathway of complement. Brief report.
    Hetland G; Bungum L
    APMIS; 1988 Jan; 96(1):89-92. PubMed ID: 3345254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Freeze-thaw activation of the complement attack phase: I. Separation of two steps in the formation of the active C--56 complex.
    Dessauer A; Rother U; Rother K
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():75-81. PubMed ID: 6587745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs.
    Rollins SA; Matis LA; Springhorn JP; Setter E; Wolff DW
    Transplantation; 1995 Dec; 60(11):1284-92. PubMed ID: 8525523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage of the fifth component of complement and generation of a functionally active C5b6-like complex by human leukocyte elastase.
    Vogt W
    Immunobiology; 2000 Jan; 201(3-4):470-7. PubMed ID: 10776801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6.
    Biesecker G; Gomez CM
    J Immunol; 1989 Apr; 142(8):2654-9. PubMed ID: 2703710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of C5a/C5a(desArg) in bovine plasma, serum and milk.
    Rainard P; Sarradin P; Paape MJ; Poutrel B
    Vet Res; 1998; 29(1):73-88. PubMed ID: 9559522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9.
    Puentes SM; Da Silva RP; Sacks DL; Hammer CH; Joiner KA
    J Immunol; 1990 Dec; 145(12):4311-6. PubMed ID: 2147941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of an activated form of human C5 (C5b-like C5) by oxygen radicals.
    von Zabern WV; Hesse D; Nolte R; Haller Y
    Immunol Lett; 1987 Feb; 14(3):209-15. PubMed ID: 3552970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that C5b recognizes and mediates C8 incorporation into the cytolytic complex of complement.
    Stewart JL; Kolb WP; Sodetz JM
    J Immunol; 1987 Sep; 139(6):1960-4. PubMed ID: 3624872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Freeze-thaw activation of the complement attack phase: II. Comparison of convertase generated C--56 with C--56 generated by freezing and thawing.
    Dessauer A; Rother U; Rother K
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():83-8. PubMed ID: 6444196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement-induced ultrastructural membrane lesions: requirement for terminal components.
    Packman CH; Rosenfeld SI; Weed RI; Leddy JP
    J Immunol; 1976 Nov; 117(5 Pt.2):1883-9. PubMed ID: 993584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
    Langone JJ; Das C; Bennett D; Terman DS
    J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.